Clinical research company Medpace Holdings (NASDAQ: MEDP) met Wall Street’s revenue expectations in Q3 2026, with sales up 8.5% year on year to $716 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $2.85 billion at the midpoint. Its GAAP profit of $4.84 per share was 9.4% above analysts’ consensus estimates.

Is now the time to buy MEDP? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Medpace’s third quarter saw steady growth, with management attributing performance to robust demand for clinical research services and a healthy pipeline of new business awards. CEO August James Troendle pointed to a record level of net new business awards and a strong win rate, particularly in traditional oncology studies. The company also noted that project cancellations, while at the higher end of normal, did not significantly impact results. CFO Kevin Brady highlighted improved utilization and low employee turnover as supporting factors for the company’s margin expansion this quarter.

Looking forward, Medpace’s guidance is shaped by expectations for continued strength in new bookings and a stable operating environment. Management emphasized that the business remains well-positioned, with a sizable backlog and ongoing investments in operational capacity. CFO Kevin Brady cautioned that the company is monitoring the impact of potential project cancellations on future growth, and noted an upcoming expansion in Cincinnati that will add operating costs in the next year. CEO Troendle added, “We see no large disconnect between analyst consensus estimates and our current modeling for 2027.”

Key insights from management’s remarks

Medpace’s management identified several factors supporting both revenue growth and margin improvement this quarter, while also providing context on strategic priorities and operational risks.

• Record new business awards: Management reported an all-time high in net new business awards, driven by strong demand in oncology research and successful client wins across both biotech and large pharmaceutical customers.
• Margin expansion from mix shift: CFO Kevin Brady attributed higher margins to a favorable project mix and lower reimbursable costs, while also noting that direct service activities are performing well and that headcount growth is being outpaced by revenue growth.
• Stable competitive environment: CEO Troendle described the external landscape as normalized, with fewer aggressive pricing tactics from competitors and a focus returning to quality deliverables rather than price-driven wins.
• Low employee turnover: Both Troendle and Brady highlighted persistently low staff attrition rates, which have contributed to operational stability and consistent project delivery, despite some industry signals of rising turnover elsewhere.
• Project cancellations remain a watchpoint: While project cancellations were at the higher end of the typical range, Troendle explained these were mostly due to trial product failures, rather than funding constraints or macroeconomic pressures. He noted that cancellation trends remain unpredictable and warrant ongoing attention.

Drivers of future performance

Medpace’s outlook for the coming quarters hinges on the sustainability of new business wins, backlog conversion, and continued discipline in operations and hiring.

• Sustained bookings momentum: Management expects continued growth in new business awards, underpinned by a large pipeline of requests for proposals and strong client demand, particularly in oncology and metabolic research. The company views backlog conversion rates as a key determinant of near-term revenue growth.
• Operational investments and cost control: The upcoming Cincinnati campus expansion will introduce higher operating expenses in the next year, but management believes ongoing efficiency initiatives and stable headcount turnover will help offset cost pressures.
• Risks from project cancellations: Management flagged that project cancellations, often tied to product failures in client trials, remain a variable factor that could impact future revenue recognition and growth rates. The company is monitoring this closely as it finalizes guidance for next year.

Catalysts in upcoming quarters

In the coming quarters, the StockStory team will be watching (1) whether Medpace can maintain strong new business awards and backlog conversion rates, (2) the impact of the Cincinnati expansion on cost structure and margins, and (3) any shifts in project cancellation rates, particularly as product failures or industry headwinds emerge. Progress on operational efficiency and sustained demand in core therapeutic areas will also be important indicators.

Medpace currently trades at $666.40, in line with $664 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Now could be the perfect time to invest in these stocks

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.